Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention
Table 1
Baseline characteristics.
Variables
Overall population
Propensity score-matched population
Clopidogrel (n=283)
Ticagrelor (n=270)
P value
Clopidogrel (n=240)
Ticagrelor (n=240)
P value
Demographics
Age, years
64.43±11.10
63.37±10.55
0.250
64.15±11.29
64.00±10.39
0.880
Age (<65), n (%)
131(46.30)
128(47.41)
0.792
113(47.08)
108(45.00)
0.647
Women, n (%)
74(26.15)
66(24.44)
0.645
63(26.25)
61(25.42)
0.835
Cardiovascular risk factors
Smoking, n (%)
136(48.06)
139(51.48)
0.421
115(47.92)
120(50.00)
0.648
Hypertension, n (%)
166(58.66)
158(58.52)
0.974
141(58.75)
137(57.08)
0.712
Dyslipidemia, n (%)
78(27.56)
80(29.63)
0.591
64(26.67)
71(29.58)
0.477
Diabetes, n (%)
74(26.15)
76(28.15)
0.597
59(24.58)
61(25.42)
0.833
Clinical History
Peripheral artery disease, n (%)
56(19.79)
57(21.11)
0.700
51(21.25)
49(20.62)
0.822
Previous MI, n (%)
21(7.42)
21(7.78)
0.874
17(7.08)
18(7.50)
0.861
Previous PCI, n (%)
22(7.77)
34(12.59)
0.060
22(9.17)
20(8.33)
0.747
Physical findings
Systolic Blood Pressure, mmHg
132.48±20.43
132.52±19.62
0.984
132.45±20.03
132.58±19.66
0.943
diastolic blood pressure, mmHg
77.65±12.50
77.60±12.34
0.965
78.11±12.81
77.32±12.39
0.492
Heart rates, bpm
76.26±11.81
76.47±11.45
0.830
76.65±11.93
76.25±11.54
0.709
Clinical diagnosis
0.698
0.550
Stable angina, n (%)
37(13.07)
29(10.74)
35(14.58)
27(11.25)
ACS, n (%)
231(81.63)
226(83.70)
192(80.00)
200(83.33)
Others, n (%)
15(5.30)
15(5.56)
13(5.42)
13(5.42)
Medication persistent to 1year
RAS blocker, n (%)
226(79.86)
214(79.26)
0.861
192(80.00)
189(78.75)
0.735
Beta-blocker, n (%)
198(69.96)
191(70.74)
0.842
178(74.17)
171(71.25)
0.473
Statin, n (%)
280(98.94)
269(99.63)
0.339
239(99.58)
239(99.58)
1.000
Results are expressed as mean±standard or n (%). MI: myocardial infarction, PCI: percutaneous coronary intervention, ACS: acute coronary syndrome, and RAS: renin-angiotensin system.
